How do I… facilitate a rapid response to a public health emergency requiring plasma collection with a public–private partnership?. Issue 10 (12th September 2021)

• Record Type: Journal Article
• Authors: Miller, Maureen J.; Skrzekut, Adam; Kracalik, Ian; Jones, Jefferson M.; Lofy, Kathryn H.; Konkle, Barbara A.; Haley, N. Rebecca; Duvenhage, Michael; Bonnett, Tyler; Holbrook, Michael; Higgs, Elizabeth; Basavaraju, Sridhar V.; Paranjape, Suman
• Is Part Of: Transfusion. Volume 61:Issue 10(2021)
• Page Start: 2814
• Page End: 2824
• Publication Date: 2021-09-12
• Subjects: administration -- blood center operations -- donors; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.16630
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract: In March 2020, there were no treatment options for COVID‐19. Passive immune therapy including anti‐SARS‐CoV‐2 hyperimmune globulin (hIVIG) was a logical candidate for COVID‐19 therapeutic trials, given past success treating emerging pathogens with endogenous neutralizing antibodies. We established a plasma collection protocol for persons recovered from COVID‐19. To speed recruitment in the first U.S. hotspot, Seattle, Washington, federal and state public health agencies collaborated with Bloodworks Northwest to collect convalescent plasma (CP) for manufacturing hIVIG. During March–December 2020, we identified and recruited prospective CP donors via letters to persons recovered from COVID‐19 with laboratory‐confirmed SARS‐CoV‐2 infection. Prospective donors were pre‐screened and administered a medical history survey. Anti‐SARS‐CoV‐2 neutralizing antibody (NAb) titers were classified as qualifying (≥1:80) or non‐qualifying (<1:80) for enrollment based on a live virus neutralization assay. Generalized estimating equations were used to identify characteristics of donors associated with qualifying versus nonqualifying NAb titers. Overall, 21, 359 letters resulted in 3207 inquiries, 2159 prescreenings with laboratory‐confirmed SARS‐CoV‐2 infection, and 573 donors (27% of all pre‐screenings with confirmed infection) who provided a screening plasma donation. Of 573 donors screened, 254 (44%) provided plasma with qualifying NAb titers, resulting in 1284 units for hIVIG manufacture. In a multivariable model, after adjusting for other factors, time (60 days) from COVID‐19 symptom onset to screening was associated with lower odds of qualifying NAb (adjusted odds ratio = 0.67, 95% CI: 0.48–0.94). The collaboration facilitated a rapid response to develop and provide hIVIG for clinical trials and CP for transfusion. Only 1 in 12 donor inquiries resulted in a qualifying plasma donation. Challenges included recruitment and the relatively low percentage of persons with high NAb titers and limited screening capacity. This resource‐intensive collaboration may not be scalable but informs preparedness and response strategies for plasma collection in future epidemics. Operational readiness plans with templates for screening, consent, and data collection forms are recommended.